Skip to main content
Top
Published in: International Journal of Hematology 2/2016

01-08-2016 | Letter to the Editor

JAK2, MPL, and CALR mutations in children with essential thrombocythemia

Authors: Yuko Sekiya, Yusuke Okuno, Hideki Muramatsu, Olfat Ismael, Nozomu Kawashima, Atsushi Narita, Xinan Wang, Yinyan Xu, Asahito Hama, Hiroyuki Fujisaki, Toshihiko Imamura, Daiichiro Hasegawa, Yoshiyuki Kosaka, Shosuke Sunami, Yoshitoshi Ohtsuka, Shouichi Ohga, Yoshiyuki Takahashi, Seiji Kojima, Akira Shimada

Published in: International Journal of Hematology | Issue 2/2016

Login to get access

Excerpt

Essential thrombocythemia (ET) is an intractable clonal stem cell disorder characterized by a marked increase in platelet count [1]. It is extremely rare among children. Somatic mutations in JAK2 and MPL cause ET, and recent comprehensive genomics studies of adult ET have identified CALR, which encodes calreticulin, as a novel causative gene. Subsequent study revealed that genotype defines the clinical characteristics of ET [2]; patients with JAK2 mutations are at higher risk of thrombosis than those with CALR mutations. These findings highlight the clinical importance of molecular diagnosis. …
Appendix
Available only for authorised users
Literature
1.
go back to reference Fu R, Zhang L, Yang R. Paediatric essential thrombocythemia: clinical and molecular features, diagnosis and treatment. Br J Haematol. 2013;163(3):295–302.CrossRefPubMed Fu R, Zhang L, Yang R. Paediatric essential thrombocythemia: clinical and molecular features, diagnosis and treatment. Br J Haematol. 2013;163(3):295–302.CrossRefPubMed
2.
go back to reference Rumi E, Pietra D, Ferretti V, Klampfl T, Harutyunyan AS, Milosevic JD, et al. JAK2 or CALR mutation status defines subtypes of essential thrombocythemia with substantially different clinical course and outcomes. Blood. 2014;123(10):1544–51.CrossRefPubMedPubMedCentral Rumi E, Pietra D, Ferretti V, Klampfl T, Harutyunyan AS, Milosevic JD, et al. JAK2 or CALR mutation status defines subtypes of essential thrombocythemia with substantially different clinical course and outcomes. Blood. 2014;123(10):1544–51.CrossRefPubMedPubMedCentral
3.
go back to reference Giona F, Teofili L, Capodimonti S, Laurino M, Martini M, Marzella D, et al. CALR mutations in patients with essential thrombocythemia diagnosed in childhood and adolescence. Blood. 2014;123(23):3677–9.CrossRefPubMed Giona F, Teofili L, Capodimonti S, Laurino M, Martini M, Marzella D, et al. CALR mutations in patients with essential thrombocythemia diagnosed in childhood and adolescence. Blood. 2014;123(23):3677–9.CrossRefPubMed
Metadata
Title
JAK2, MPL, and CALR mutations in children with essential thrombocythemia
Authors
Yuko Sekiya
Yusuke Okuno
Hideki Muramatsu
Olfat Ismael
Nozomu Kawashima
Atsushi Narita
Xinan Wang
Yinyan Xu
Asahito Hama
Hiroyuki Fujisaki
Toshihiko Imamura
Daiichiro Hasegawa
Yoshiyuki Kosaka
Shosuke Sunami
Yoshitoshi Ohtsuka
Shouichi Ohga
Yoshiyuki Takahashi
Seiji Kojima
Akira Shimada
Publication date
01-08-2016
Publisher
Springer Japan
Published in
International Journal of Hematology / Issue 2/2016
Print ISSN: 0925-5710
Electronic ISSN: 1865-3774
DOI
https://doi.org/10.1007/s12185-016-2022-2

Other articles of this Issue 2/2016

International Journal of Hematology 2/2016 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine